Available Dosages
| SKU: | 1085 |
|---|---|
| Generic For: | Micardis |
| Active Ingredient: | Telmisartan |
| Manufacturer: | Glenmark, India |
Buy Telma 80mg (Telmisartan) Online
Telma 80mg is a prescription oral tablet containing Telmisartan 80mg, the maximum approved dose of this once-daily angiotensin II receptor blocker (ARB), used in patients with hypertension that remains inadequately controlled at the 40mg dose and in patients with established cardiovascular disease or diabetic nephropathy who require high-dose ARB therapy for both blood pressure control and organ protection. Telma 80mg represents the full therapeutic ceiling of the Telmisartan dose range — delivering maximum AT1 receptor blockade, the most complete suppression of the renin-angiotensin-aldosterone system (RAAS) achievable with Telmisartan monotherapy, and the highest magnitude of the PPAR-γ partial agonist activity that differentiates Telmisartan from other ARBs in its cardiometabolic profile. Its clinical validation in major outcome trials — most notably ONTARGET, in which Telmisartan 80mg daily was shown to be non-inferior to Ramipril 10mg in reducing major cardiovascular events in high-risk patients — positions it as one of the most evidence-backed ARBs for cardiovascular risk reduction, not merely blood pressure control.
What is Telma 80mg?
Telma 80mg is an oral tablet containing Telmisartan 80mg, the highest dose in the Telmisartan range, used when the 40mg dose has not achieved target blood pressure goals or when the clinical indication — particularly diabetic nephropathy, proteinuria reduction, or high cardiovascular risk requiring maximal RAAS suppression — demands the strongest degree of AT1 receptor blockade available from this molecule. At 80mg once daily, Telmisartan achieves near-maximal AT1R occupancy, producing the greatest reduction in angiotensin II-mediated vasoconstriction, the most complete suppression of aldosterone secretion, and the strongest natriuretic effect within the dose-response curve. This translates to additional blood pressure-lowering beyond the 40mg dose — typically a 3 to 5 mmHg further reduction in systolic blood pressure — that can be the difference between controlled and uncontrolled hypertension in patients with stage 2 hypertension or secondary resistance. Beyond blood pressure, Telmisartan 80mg is the dose used in the landmark ONTARGET trial and in clinical practice for cardioprotection in post-MI patients and patients with multiple cardiovascular risk factors who cannot tolerate ACE inhibitors.
Manufacturer: Telma 80mg is manufactured by Glenmark Pharmaceuticals Ltd., a globally recognised Indian pharmaceutical company with internationally certified manufacturing facilities and a comprehensive cardiovascular and metabolic medicine portfolio.
Key Ingredients of Telma 80mg and Their Working Process
Telmisartan 80mg achieves its antihypertensive and organ-protective effects through the same AT1 receptor antagonism mechanism as lower doses, but at a level of receptor occupancy that produces the maximum pharmacodynamic effect available from Telmisartan. By saturating AT1R binding sites in vascular smooth muscle, the adrenal cortex, cardiac tissue, and renal mesangial and tubular cells, Telmisartan 80mg removes angiotensin II’s influence across the full spectrum of target tissues. In the kidney, high-dose AT1R blockade reduces efferent arteriolar tone more effectively than lower doses, decreasing intraglomerular capillary pressure and thereby reducing the filtration of large protein molecules — the mechanism underlying Telmisartan 80mg’s antiproteinuric and renoprotective effects in diabetic nephropathy. Reduced intraglomerular pressure slows the rate of glomerular scarring. It delays the progression of diabetic kidney disease to end-stage renal failure, an outcome with enormous clinical significance given the prevalence of CKD in patients with long-standing type 2 diabetes and hypertension.
At the 80mg dose, Telmisartan’s partial PPAR-γ agonist activity is at its greatest clinical magnitude. This activity — documented through improvements in insulin sensitivity indices, reductions in fasting glucose, and favourable changes in lipid profile in clinical studies comparing Telmisartan to other ARBs at equivalent blood pressure reduction — works in concert with the AT1R blockade to provide comprehensive cardiometabolic risk modification. For patients in whom both blood pressure control and metabolic risk factor management are required, the 80mg dose represents the strongest single-agent expression of Telmisartan’s dual mechanism.
Clinical Uses of Telmisartan 80mg
Telmisartan 80mg is indicated for patients whose hypertension is not controlled at 40mg as monotherapy, and as the dose of choice for specific high-risk indications where maximum RAAS blockade is the therapeutic objective. In diabetic nephropathy — the leading cause of end-stage kidney disease globally — Telmisartan 80mg is used alongside glycaemic control and statin therapy to reduce proteinuria and slow the progression of CKD. The AMADEO trial demonstrated that Telmisartan 80mg was at least as effective as Losartan 100mg in reducing proteinuria in patients with diabetic nephropathy, with additional antihypertensive benefit.
Comparing Telma 80mg and Micardis 80mg: Brand vs Generic Differences
Micardis 80mg (Boehringer Ingelheim) is the branded Telmisartan product used in the ONTARGET, TRANSCEND, and AMADEO trials — the pivotal studies that established Telmisartan’s cardiovascular and renoprotective outcomes evidence at the 80mg dose. Telma 80mg from Glenmark Pharmaceuticals contains Telmisartan 80mg and is formulated to deliver bioequivalent plasma exposure to Micardis 80mg: equivalent Cmax, AUC, and terminal half-life, confirming that AT1R occupancy, duration of action, and pharmacodynamic effects are interchangeable between the two products. The outcomes demonstrated in the Micardis 80mg trial programme — non-inferiority to Ramipril in cardiovascular outcomes, renoprotection in diabetic nephropathy, 24-hour blood pressure control — are pharmacologically applicable to Telma 80mg as a bioequivalent formulation. Micardis 80mg commands the highest price among Telmisartan doses in all markets; Telma 80mg from Glenmark provides the same evidence-based, maximum-dose Telmisartan therapy at substantially lower cost, directly improving access to the full ARB dose range for patients who need it.
Related strengths and products: Patients initiating Telmisartan therapy begin with Telma 20mg before titrating to Telma 40mg as the standard maintenance dose. Telma 80mg is the escalation option for those requiring maximum dose ARB therapy. The complete Telma range provides a seamless dose-escalation pathway from initiation to the maximum therapeutic dose within a single brand.
Key Benefits of Telma 80mg
Telma 80mg delivers the maximum antihypertensive effect available from Telmisartan, providing the additional blood pressure reduction needed by patients who have not reached target on 40mg — with the same once-daily convenience and 24-hour duration of action that characterises the entire Telmisartan class. The clinical trial evidence at the 80mg dose — particularly the ONTARGET non-inferiority data against Ramipril — provides strong support for Telmisartan 80mg as a first-choice ARB when cardiovascular event risk reduction, not merely blood pressure control, is the therapeutic goal. The combination of maximum AT1R blockade and peak PPAR-γ agonist activity at 80mg represents the most complete expression of Telmisartan’s dual cardiometabolic mechanism, providing benefits in both the vascular and metabolic domains relevant to hypertensive patients with diabetes, dyslipidaemia, or metabolic syndrome. The absence of ACE inhibitor-associated cough makes Telmisartan 80mg a well-tolerated long-term option for patients in whom maximum RAAS blockade is required, but ACE inhibitor side effects have previously limited therapy.
Usage warnings and precautionary advice for using Telmisartan 80mg
All precautions applicable to Telmisartan at lower doses apply with greater clinical importance at the 80mg dose, where RAAS suppression is at its most complete. Pregnancy remains an absolute contraindication — Telmisartan 80mg must be stopped immediately if pregnancy is confirmed or suspected, and women of reproductive age must use reliable contraception throughout therapy. A greater degree of AT1R blockade at 80mg is associated with an increased risk of hyperkalaemia and ARB-related renal effects; potassium and creatinine monitoring must be performed at initiation and at regular intervals thereafter, with greater vigilance required in patients with diabetes, CKD, or concurrent use of potassium-sparing diuretics. Dual RAAS blockade — combining Telmisartan 80mg with an ACE inhibitor or aliskiren — is associated with significantly increased risk of hypotension, hyperkalaemia, and acute kidney injury, and is contraindicated in patients with diabetes or renal impairment by major guidelines. In patients taking NSAIDs, which blunt the vasodilatory prostaglandin effects in the kidney, both antihypertensive efficacy and renal protection may be attenuated, and renal function may deteriorate; this combination requires careful monitoring. Hepatic impairment reduces Telmisartan clearance, and the 80mg dose should be used with particular caution in patients with significant liver disease.
Side effects of Telmisartan 80mg
At the 80mg dose, Telmisartan is generally well tolerated, though the side effect risks inherent to AT1R blockade are at their maximum. Hyperkalaemia is the most important laboratory side effect to monitor — it is usually asymptomatic but clinically significant, particularly in patients with renal impairment, diabetes, or on other potassium-elevating medications. Dizziness and symptomatic hypotension are more likely at 80mg than at lower doses, especially in volume-depleted patients or those on concurrent diuretic therapy; these effects are typically most prominent in the first days to weeks of dose escalation and usually resolve with continued therapy. Back pain, upper respiratory tract infections, and diarrhoea are reported at rates broadly similar to placebo across clinical trial data. Headache and fatigue occur in a minority of patients. Renal function changes — including a modest initial rise in serum creatinine reflecting the reduction in intraglomerular pressure — are expected in patients with CKD or diabetes and do not require discontinuation unless the rise is large or accompanied by a rise in potassium to dangerous levels. Angioedema — though far less common with ARBs than ACE inhibitors — can occur and requires immediate permanent discontinuation. At 80mg, as at all doses, Telmisartan does not cause the cough associated with ACE inhibitors, preserving its tolerability advantage for long-term cardiovascular risk management.
Benefits of Buying Telma 80mg Online from AllDayChemist
Telma 80mg can be bought online at competitive prices with reliable international home delivery from AllDayChemist. Here, you get vital access to medicines that require maximum-dose ARB therapy for long-term cardiovascular risk reduction or diabetic kidney protection. High-dose antihypertensive therapy for complex patients is a lifelong commitment; AllDayChemist’s dependable supply chain and convenient repeat-order service help ensure therapy continuity, which is directly linked to long-term blood pressure control and cardiovascular outcomes.
Proper dosage and usage guide of Telmisartan 80mg
Telma 80mg should be taken orally once daily at a consistent time, swallowed whole with water. The tablet may be taken with or without food; food does not significantly affect Telmisartan bioavailability. The 80mg dose is typically reached after a period of therapy at 40mg — do not initiate directly at 80mg without physician guidance, as this bypasses the opportunity to assess tolerability at lower doses and risks an excessive initial blood pressure reduction in sensitive patients. Once established at 80mg, blood pressure should be monitored to confirm that target levels are being achieved; if not, combination antihypertensive therapy — with a thiazide diuretic or amlodipine — rather than further dose escalation (which is not appropriate, as 80mg is the maximum) is the next clinical step. Renal function and serum potassium monitoring are especially important at the 80mg dose, given the greater degree of RAAS suppression and its effects on kidney potassium handling. Never stop Telmisartan abruptly without physician guidance — while ARBs do not cause rebound hypertension as severe as some other antihypertensive classes, gradual discontinuation with blood pressure monitoring is always preferable. Store below 30°C in a dry place away from moisture and direct light.
Leading Online Pharmacy
100% Genuine
Products
& OTC Products
Login
Sign up
Leading Online Pharmacy
100% Genuine
Products
& OTC Products
Login
Sign Up
Leading Online Pharmacy
100% Genuine
Products
& OTC Products
Forgot Password ?